SCHEMBL3485918

SCHEMBL3485918

CC(C)N(C1CCN(CC(=O)Nc2ccc(F)cc2)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
ALDH1A1 P00352 9/20 0.52
LMNA P02545 5/20 0.52
MAPT P10636 4/20 0.52
HSD17B10 Q99714 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
POLB P06746 2/20 0.49
HTT P42858 2/20 0.47
CACNA1B Q00975 2/20 0.47
CYP3A4 P08684 2/20 0.47
USP2 O75604 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
MCOLN3 Q8TDD5 1/20 0.47
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA4 P43681 1/20 0.46
TP53 P04637 1/20 0.46
UBE2M P61081 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485824 0.94 ALDH1A1 (0.52) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3485688 0.92 ALDH1A1 (0.50) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3485549 0.91 UBE2M (0.48) TSHRALDH1A1LMNASMN1; SMN2POLB
SCHEMBL3485300 0.91 SMN1; SMN2 (0.52) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3485926 0.90 CACNA1B (0.53) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3484989 0.90 RORC (0.55) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3485838 0.89 TSHR (0.58) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3485705 0.89 ALDH1A1 (0.54) TSHRALDH1A1LMNAMAPTHSD17B10
SCHEMBL3485141 0.88 POLB (0.49) TSHRALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3485265 0.87 ALDH1A1 (0.47) TSHRALDH1A1LMNAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B TSHR 2248/4885ALDH1A1 2210/4885LMNA 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.